Selective Targeting of a Redox-active Ubiquinone to Mitochondria within Cells

ANTIOXIDANT AND ANTIAPOPTOTIC PROPERTIES*

Geoffrey F. KelsoDagger §, Carolyn M. Porteous, Carolyn V. CoulterDagger ||, Gillian Hughes, William K. Porteous, Elizabeth C. Ledgerwood**, Robin A. J. SmithDagger , and Michael P. MurphyDaggerDagger

From the Departments of Dagger  Chemistry and  Biochemistry, University of Otago, Box 56, Dunedin, New Zealand

Received for publication, October 5, 2000, and in revised form, November 21, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

With the recognition of the central role of mitochondria in apoptosis, there is a need to develop specific tools to manipulate mitochondrial function within cells. Here we report on the development of a novel antioxidant that selectively blocks mitochondrial oxidative damage, enabling the roles of mitochondrial oxidative stress in different types of cell death to be inferred. This antioxidant, named mitoQ, is a ubiquinone derivative targeted to mitochondria by covalent attachment to a lipophilic triphenylphosphonium cation through an aliphatic carbon chain. Due to the large mitochondrial membrane potential, the cation was accumulated within mitochondria inside cells, where the ubiquinone moiety inserted into the lipid bilayer and was reduced by the respiratory chain. The ubiquinol derivative thus formed was an effective antioxidant that prevented lipid peroxidation and protected mitochondria from oxidative damage. After detoxifying a reactive oxygen species, the ubiquinol moiety was regenerated by the respiratory chain enabling its antioxidant activity to be recycled. In cell culture studies, the mitochondrially localized antioxidant protected mammalian cells from hydrogen peroxide-induced apoptosis but not from apoptosis induced by staurosporine or tumor necrosis factor-alpha . This was compared with untargeted ubiquinone analogs, which were ineffective in preventing apoptosis. These results suggest that mitochondrial oxidative stress may be a critical step in apoptosis induced by hydrogen peroxide but not for apoptosis induced by staurosporine or tumor necrosis factor-alpha . We have shown that selectively manipulating mitochondrial antioxidant status with targeted and recyclable antioxidants is a feasible approach to investigate the role of mitochondrial oxidative damage in apoptotic cell death. This approach will have further applications in investigating mitochondrial dysfunction in a range of experimental models.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

The mitochondrial respiratory chain is a major source of superoxide and, therefore, mitochondria accumulate oxidative damage more rapidly than the rest of the cell, contributing to mitochondrial dysfunction and cell death in degenerative diseases and in aging (1-5). Mitochondria are also central to activating apoptosis and oxidative damage can lead to cell death, however, the significance of mitochondrial oxidative damage for cell death is unclear (6-8). One approach to this problem is to selectively target antioxidants to mitochondria (9-11). This should allow the relative importance of mitochondrial and cytoplasmic oxidative stress for cell death to be distinguished, and also enable the contribution of mitochondrial damage to aging, diabetes, and cancer to be investigated in cell and animal models.

Derivatives of ubiquinol are promising antioxidants to target to mitochondria (11, 12). In mammals ubiquinone comprises a 2,3-dimethoxy-5-methylbenzoquinone core with a hydrophobic 45- to 50-carbon chain at the 6 position (13, 14). Mitochondrial ubiquinone is a respiratory chain component buried within the lipid core of the inner membrane where it accepts two electrons from complexes I or II becoming reduced to ubiquinol, which then donates electrons to complex III (14). The ubiquinone pool in vivo is largely reduced and ubiquinol is an effective antioxidant, as well as being a mobile electron carrier (15-18). Ubiquinol acts as an antioxidant by donating a hydrogen atom from one of its hydroxyl groups to a lipid peroxyl radical, thereby decreasing lipid peroxidation within the mitochondrial inner membrane (18-20). The ubisemiquinone radicals thus formed disproportionate to ubiquinone and ubiquinol (21), or react with oxygen to form superoxide and ubiquinone thereby transferring the radical to the aqueous phase for detoxification by superoxide dismutase and peroxidases (17, 20). The respiratory chain then recycles ubiquinone back to ubiquinol to restore its antioxidant function. Vitamin E is another important antioxidant within the mitochondrial inner membrane, and the tocopheroxyl radical thus formed is regenerated to active vitamin E by reaction with ubiquinol or ubisemiquinone (15, 17, 20, 22, 23). Therefore, in vivo ubiquinol probably acts as an antioxidant by direct reaction with peroxyl radicals and by regenerating vitamin E (16, 17, 20).

The low solubility of ubiquinone in water makes it difficult to use in vitro, and animals must be fed ubiquinone-enriched diets for several weeks to increase levels in subsequently isolated mitochondria (11, 14). Therefore, to manipulate mitochondrial ubiquinone content in vitro we synthesized a ubiquinone analog selectively targeted to mitochondria by addition of a lipophilic triphenylphosphonium cation. Such lipophilic cations easily permeate lipid bilayers and accumulate in mitochondria within cells, driven by the large mitochondrial membrane potential (9, 10, 24). Here we report on the antioxidant and antiapoptotic properties of this mitochondrially targeted ubiquinone derivative.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

Chemical Syntheses-- To synthesize 11-bromoundecanoic peroxide (1) 11-bromoundecanoic acid (4.00 g, 15.1 mmol) and SOCl2 (1.6 ml, 21.5 mmol) were heated at 90 °C for 15 min (25). Excess SOCl2 was removed by distillation under reduced pressure (15 mm Hg, 90 °C) and the residue (IR,1 1799 cm-1) was dissolved in diethyl ether (20 ml) and cooled to 0 °C. Hydrogen peroxide (30%, 1.8 ml) was added, followed by dropwise addition of pyridine (1.4 ml) over 45 min, then diethyl ether (10 ml) was added and after 1 h at room temperature the product was diluted with diethyl ether (150 ml), washed with H2O (2 × 70 ml), 1.2 M HCl (2 × 70 ml), H2O (70 ml), 0.5 M NaHCO3 (2 × 70 ml), and H2O (70 ml). After drying over MgSO4 the solvent was removed at room temperature under reduced pressure, giving crude 1 as a white solid (3.51 g), which was used without delay. IR (Nujol mull) 1810, 1782 cm-1.

6-(10-Bromodecyl)ubiquinone (2) was synthesized by stirring crude 1 (3.51 g, 12.5 mmol), 2,3-dimethoxy-5-methyl-1,4-benzoquinone (1.31 g, 7.19 mmol, Aldrich), and acetic acid (60 ml) for 20 h at 100 °C. After cooling to room temperature, the reaction was diluted with diethyl ether (600 ml), washed with H2O (2 × 400 ml), 1 M HCl (2 × 450 ml), 0.5 M NaHCO3 (2 × 450 ml), and H2O (2 × 400 ml), and dried over MgSO4. Removal of the solvent under reduced pressure gave a reddish solid (4.31 g). Column chromatography on silica gel, eluting with CH2Cl2, gave 2 as a red oil (809 mg, 28%) and unreacted 2,3-dimethoxy-5-methyl-1,4-benzoquinone (300 mg, 1.6 mmol, 13%). 2: TLC: RF (CH2Cl2, diethyl ether 20:1) 0.46; IR (film) 2928, 2854, 1650, 1611, 1456, 1288 cm-1; lambda max (ethanol): 278 nm; 1H NMR (299.9 MHz) 3.99 (s, 6H, 2 x-OCH3), 3.41 (t, J = 6.8 Hz, 2H, -CH2-Br), 2.45 (t, J = 7.7 Hz, 2H, ubquinone-CH2-), 2.02, (s, 3H, -CH3). 1.89 (quin, J = 7.4 Hz, 2H, -CH2 -CH2-Br), 1.42-1.28 (m, 14H, -(CH2)7-) ppm; 13C NMR (125.7 MHz) 184.7 (C = O), 184.2 (C = O), 144.3 (2C, ring), 143.1 (ring), 138.7 (ring), 61.2 (2× -OCH3), 34.0 (-CH2-), 32.8 (-CH2-), 29.8 (-CH2-), 29.4 (2× -CH2-), 29.3 (-CH2-), 28.7 (2× -CH2-), 28.2 (-CH2-), 26.4 (-CH2-), 11.9 (-CH3) ppm. Anal. calcd. for C19H29O4Br: C, 56.86; H, 7.28; found: C, 56.49, H, 7.34%; mass spectrum: calcd. for C19H29O4Br 400/402; found 400/402.

To form the quinol, 6-(10-bromodecyl)-ubiquinol (3), NaBH4 (295 mg, 7.80 mmol) was added to 2 (649 mg, 1.62 mmol) in methanol (6 ml) and stirred under argon for 10 min (Scheme 1). Excess NaBH4 was quenched with 5% HCl (2 ml), diluted with diethyl ether (40 ml), washed with 1.2 M HCl (40 ml), saturated NaCl (2 × 40 ml), and dried over MgSO4. Removal of the solvent under reduced pressure gave 3 as a yellow oily solid (541 mg, 83%). 1H NMR (299.9 MHz) 5.31 (s, 1H, -OH), 5.26 (s, 1H, -OH), 3.89 (s, 6H, 2× -OCH3), 3.41 (t, J = 6.8 Hz, 2H, -CH2-Br), 2.59 (t, J = 7.7 Hz, 2H ubquinol-CH2-), 2.15 (s, 3H, CH3), 1.85 (quin, J = 7.4 Hz, 2H, -CH2-CH2-Br), 1.44-1.21 (m, 14H, -(CH2)7-) ppm.



View larger version (12K):
[in this window]
[in a new window]
 
Scheme 1.   Synthesis of mitoquinol (4) and mitoquinone (5). Numbers refer to percentage yields for syntheses.

To synthesize 10-(6'-ubiquinolyl)decyltriphenylphosphonium bromide (4), triphenylphosphine (387 mg, 1.48 mmol), 3 (541 mg, 1.34 mmol), and ethanol (95%, 2.5 ml) were sealed under argon in a 15-ml Kimax tube and stirred in the dark for 88 h at 85 °C. Removal of the solvent under reduced pressure gave an oily orange residue, which was dissolved in CH2Cl2 (2 ml). Addition of diethyl ether (20 ml) gave a suspension, and after 5 min the supernatant was decanted. The residue was dissolved in CH2Cl2 (2 ml) followed by addition of diethyl ether (20 ml), and the supernatant was decanted. The CH2Cl2/diethyl ether extraction was repeated twice more, and residual solvent was removed under reduced pressure, giving crude 4 as a cream solid (507 mg). 1H NMR (299.9 MHz) 7.9-7.6 (m, 15H, -P+ Ph3), 3.89 (s, 6H, 2× -OCH3), 3.91-3.77 (m, 2H, -CH2-P+Ph3), 2.57 (t, J = 7.8 Hz, 2H ubquinol-CH2-), 2.14 (s, 3H, CH3), 1.6-1.2 (m, 16H, -(CH2)8-) ppm. 31P NMR (121.4 MHz) 25.1 ppm.

Crude 4 (200 mg) was oxidized to 10-(6'-ubiquinonyl)decyltriphenyl-phosphonium bromide (5) by stirring in CDCl3 at room temperature under an oxygen atmosphere. The solvent was removed under reduced pressure, the residue was dissolved in CH2Cl2 (5 ml), diethyl ether (15 ml) was added, and the resultant suspension was stirred for 5 min. The supernatant was decanted, and the CH2Cl2/diethyl ether precipitation was repeated twice more. Residual solvent was removed under reduced pressure, giving crude 5 as a brown sticky solid (173 mg). IR (film) 3357, 2927, 2857, 1650, 1609, 1438, 1266, 1113 cm-1. 1H NMR (299.9 MHz) 7.9-7.6 (m, 15H-P+Ph3), 3.98 (s, 6H, 2× -OCH3), 3.93-3.8 (m, 2H, -CH2-P+Ph3), 2.42 (t, J = 7.4 Hz, 2H, ubiquinone-CH2-), 2.00 (s, 3H, CH3), 1.6-1.2 (m, 16H, (CH2)8-) ppm; 13C NMR (75.4 MHz) 184.8 (C=O), 184.2 (C=O) 144.3 (2C, ring), 143.1 (ring), 138.8 (ring). 135.0 (d, J = 2.4 Hz, -P+Ph3 para), 133.8 (d, J = 85.0 Hz, -P+Ph3 ortho/meta), 130.5 (d, J = 13.3 Hz, P+Ph3 ortho/meta), 118.6 (d, J = 85.0 Hz, P+Ph3 ipso); 30.4 (d, J = 15.8 Hz, -CH2-CH2-CH2-P+Ph3), 29.8 (-CH2-), 29.3 (-CH2-), 29.2 (2× -CH2-), 29.1 (-CH2-), 28.7 (-CH2-), 26.4 (-CH2-), 22.9 (d, J = 48.5 Hz, -CH2-P+Ph3), 22.7 (d, J = 4.9 Hz, -CH2-CH2-P+Ph3), 11.9 (-CH3) ppm. 31P NMR (121.4 MHz) 25.1 ppm. Anal. calcd. for C37H44O4PBr: C, 66.97; H 6.68; found: C, 66.69; H, 6.99; mass spectrum: calcd. for C37H44O4P 583.2977; found 583.2972.

To synthesize 3H-enriched 10-(6'-ubiquinolyl)decyltriphenylphosphonium bromide, triphenylphosphine (4.09 mg; 15.6 µmol), 3 (6.3 mg; 15.6 µmol), and 250 µl of ethanol containing [3H]triphenylphosphine (74 µCi, Moravek Biochemicals, Brea, CA, 1 Ci/mmol) were sealed under argon in a Kimax tube and stirred in the dark for 55 h at 80 °C. After cooling the product was precipitated by addition of diethyl ether, and the orange solid was dissolved in a few drops of CH2Cl2 and precipitated with diethyl ether. This was repeated four times to remove unreacted triphenylphosphine and 3. Two separate syntheses of 3H-enriched 10-(6'-ubiquinonyl)decyltriphenylphosphonium bromide were carried out giving products of 2.6 and 2.46 mCi/mmol, respectively, which gave the same results in experiments with isolated mitochondria, and their UV absorption spectra were as expected for a mixture of 4 and 5. TLC followed by scintillation counting of sectioned plates and comparison with the RF values of the unlabeled compounds confirmed radiopurity.

Characterization of Products-- Stock solutions containing a mixture of 4 and 5 in ethanol were stored at -80 °C, and their concentrations were confirmed by 31P NMR. Fully oxidized solutions were generated by incubation in basic 95% ethanol on ice (13) or with beef heart mitochondrial membranes at room temperature. Both procedures gave an extinction coefficient of 10,400 M-1 cm-1 at 275 nm for the quinone, with shoulders at 263 and 268 nm corresponding to the triphenylphosphonium moiety (26, 27) and a broad shoulder at 290 nm due to the quinone (13) (Fig. 1A). Reduction with NaBH4 gave the quinol, which had local maxima at 290 nm (epsilon  = 1800 M-1 cm-1) and at 268 nm (epsilon  = 3000 M-1 cm-1) (27). The Delta epsilon ox-red at 275 nm in 50 mM sodium phosphate, pH 7.2, was 7000 M-1 cm-1. The quinone extinction coefficient (10,400 M-1 cm-1 at 275 nm) was slightly lower than that reported for other quinones (12,250 M-1 cm-1) in aqueous buffer (28). This difference was not due to an intermolecular interaction between the phosphonium and the quinone, because the absorbances of 2 and the simple phosphonium methyltriphenylphosphonium (TPMP) were additive when 50 µM of each were mixed together in either ethanol or aqueous buffer. To prepare mitoquinol an ethanolic solution was diluted in ~0.5-1 ml of water and a few grains of NaBH4 were added. After incubation on ice in the dark for 5 min, excess NaBH4 was quenched with 5% HBr (0.2 ml) and the quinol was extracted into CH2Cl2 (3 × 0.5 ml). The extract was then washed with water and 2 M NaCl, then the CH2Cl2 was removed under a stream of nitrogen. The pale yellow solid residue was dissolved in acidified 96% ethanol. The yield was typically 70-80% and, as the quinol slowly oxidized in air, it was freshly prepared and stored on ice under argon in the dark. To determine partition coefficients, compounds were added to 2 ml each of 1-octanol-saturated PBS and PBS-saturated 1-octanol then shaken at 37 °C for 30 min in the dark. After separation by centrifugation, the amounts in each phase were determined by absorption relative to standard curves in 1-octanol-saturated PBS or PBS-saturated 1-octanol.

Mitochondrial Preparations and Incubations-- Rat liver mitochondria were prepared by homogenization followed by differential centrifugation (29). Beef heart mitochondria were isolated by standard procedures, and membrane fragments were prepared by sonication followed by centrifugation (30). Protein concentrations were determined by the biuret assay using bovine serum albumin as a standard (31). Endogenous ubiquinone was removed from lyophilized beef heart mitochondria by pentane extraction, and complete extraction was confirmed by the inability of these mitochondria to oxidize NADH in the absence of added Q1 (13).

For respiration measurements, rat liver mitochondria (2 mg of protein/ml) were suspended in KCl medium (120 mM KCl, 10 mM Hepes, 1 mM EGTA, pH 7.2) at 25 °C supplemented with respiratory substrates and 1 mM phosphate in a 3-ml oxygen electrode (Rank Brothers, Bottisham, Cambridge, UK). After measuring the rate of coupled respiration 200 µM ADP was added, the rate of phosphorylating respiration was measured and then FCCP (300 nM) was added and the rate of uncoupled respiration determined. To measure membrane potential, rat liver mitochondria (2 mg of protein/ml) were incubated for 3 min in 0.5 ml of KCl medium supplemented with nigericin (1 µg/ml), 5 mM each of glutamate and malate, 1 µM TPMP, and 100 nCi/ml [3H]TPMP. After incubation the mitochondria were pelleted by centrifugation, the radioactivity in the pellet and supernatant were measured by scintillation counting, and the membrane potential was calculated using the Nernst equation, assuming a mitochondrial volume of 0.5 µl/mg of protein and that 60% of the intramitochondrial TPMP was membrane-bound (32, 33). The uptake of [3H]mitoQ by rat liver mitochondria was measured under the same conditions. Scanning spectra and kinetic measurements were made with an Aminco DW-2000 dual beam spectrophotometer using matched 1-ml quartz cuvettes at 20 °C. Beef heart mitochondrial membranes and freeze-thawed yeast mitochondria were incubated in 50 mM potassium phosphate, pH 7.2. Rat liver mitochondria were incubated in KCl medium.

Oxidative Damage Assays-- To measure thiobarbituric acid reactive species (TBARS), rat liver mitochondria (2 mg of protein/ml) were incubated at 37 °C with shaking for 45 min in 100 mM KCl, 10 mM Tris-HCl, pH 7.6. Then 0.8-ml aliquots were mixed with 400 µl of 0.5% thiobarbituric acid in 35% HClO4, heated at 100 °C for 15 min, diluted with 3 ml of water, and extracted into 3 ml of n-butanol. TBARS were determined fluorometrically (lambda excite = 515 nm; lambda emission = 553 nm) and expressed as nanomoles of MDA by comparison with standard solutions of 1,1,3,3-tetraethoxypropane processed as above. Prior to analyzing samples, their mitoQ contents were brought to the same concentration to eliminate differences in MDA formation during heating and processing. To measure the membrane potential after exposure to oxidative damage, mitochondria were pelleted by centrifugation and resuspended in KCl medium, and their membrane potentials were determined as described above.

To measure cis-parinaric acid oxidation, mitochondria (2 mg of protein/ml) were suspended in a 3-ml fluorimeter cuvette in 100 mM KCl and 10 mM Tris-HCl, pH 7.6, at 37 °C. The oxidation of cis-parinaric acid (Molecular Probes) was monitored fluorometrically (lambda excite = 324 nm; lambda emission = 413 nm). A control experiment showed that titration of cis-parinaric acid into a mitochondrial suspension initially increased the fluorescence as it partitioned into membranes, but the increase became nonlinear after about 3 µM and declined above 10 µM due to self quenching (34). Therefore, 3 µM cis-parinaric acid was used for all experiments. Peroxynitrite was synthesized from acidified H2O2 and NaNO2 in a simple flow reactor as described previously (35), concentrated by freeze fractionation and stock solutions in 1.5 M NaOH quantitated [epsilon 302 = 1.67 mM-1.cm-1 (36)].

Yeast Experiments-- The Saccharomyces cerevisiae strains used were: CY4-Delta COQ3 (MATa ura3-52 leu2-3 leu2-112 trp1-1 ade2-1 his3-11 can1-100 coq3::HIS3), kindly supplied by Prof. Ian W. Dawes, University of New South Wales, Australia (37) and CEN.PK2-1C-Delta COQ3 (CEN.PK2-1C coq3::LEU2) kindly supplied by Prof. Cathy Clarke, UCLA. Both Delta COQ3 yeast strains were auxotrophic for ubiquinone when grown on nonfermentable medium. Yeasts were grown in Erlenmeyer flasks at 28 °C under air with shaking at 200 rpm. For growth analysis, cultures in YPD (1% bacto yeast extract, 2% bactopeptone, 2% dextrose) were diluted into YPEG (1% bacto yeast extract, 2% bactopeptone, 3% ethanol, 3% glycerol) to an A600 of 0.1 and then grown in the dark while the A600 was monitored. For studies on yeast mitochondria, mitochondria were prepared from lactate-grown yeast of the CY4-Delta COQ3 and CY4 wild type strains (38). Briefly, lactate-grown yeast were isolated by centrifugation, the cell wall was removed by digestion with Zymolyase, spheroplasts were homogenized, and mitochondria were isolated by differential centrifugation. Mitochondria were stored at -80 °C in 0.6 M sorbitol, 20 mM HEPES, pH 7.4, supplemented with 10 mg/ml fatty acid-free bovine serum albumin. For spectrophotometric assays, yeast mitochondria were washed in 0.6 M sorbitol, 20 mM HEPES and freeze-thawed in 50 mM potassium phosphate, pH 7.2.

Mammalian Cell Culture-- Human osteosarcoma 143B cells were cultured at 37 °C under humidified 95% air/5% CO2 in DMEM supplemented with penicillin (100 units/ml), streptomycin (100 mg/ml), and 10% fetal calf serum. For toxicity studies, cells were grown to confluence in 24-well tissue culture dishes and incubated for 24 h with DMEM/serum containing the compound. The supernatants were then harvested, and the amount of LDH released was assayed and compared with that present in untreated wells lysed with 0.1% Triton. For uptake studies cells were suspended in 0.5 ml of DMEM supplemented with 10 mM HEPES and 5 µM [3H]mitoQ. After incubation, cells were pelleted by centrifugation, and the radioactivity in the pellet was quantitated by scintillation counting. For digitonin fractionation, cells were incubated as above, and then 500 µl of the cell suspension was mixed rapidly with 1.2 ml of ice-cold 250 mM sucrose, 20 mM MOPS pH 6.7, 3 mM EDTA, and 1 mg of digitonin, then 1 ml was layered onto 350 µl of oil (66% silicone oil/34% dioctyl pthalate) over 100 µl of 500 mM sucrose, 0.1% Triton and separated into mitochondrial and cytoplasmic fractions by centrifugation. The two fractions were assayed for citrate synthase and LDH activity or for content of radioactivity by scintillation counting (39). The Jurkat human T lymphocyte line was grown at 37 °C under humidified 95% air/5% CO2 in RPMI 1640 supplemented with penicillin (100 units/ml), streptomycin (100 mg/ml), and 10% fetal calf serum. Apoptosis was induced by addition of hydrogen peroxide (8). Caspase activation in lysed cell pellets was measured fluorometrically by the cleavage of the peptide DEVD labeled with AMC (DEVD-AMC) and calibrated using an AMC standard curve (40). The proportion of cells undergoing apoptosis was quantitated by annexin V-fluorescein isothiocyanate staining followed by detection of annexin-positive cells using a Becton Dickinson FACScan flow cytometer.

General Procedures-- Column chromatography was on Silica Gel type 60, 200-400 mesh, 40-63 µm (Merck). TLC was on Silica Gel 60F 254 (Merck) or on C-18 silica (Whatman). Nuclear magnetic resonance spectra were acquired on Varian 500 MHz or Varian 300 MHz instruments in CDCl3. Chemical shifts are in delta  units (ppm) downfield from tetramethylsilane for 1H NMR and 13C NMR and 85% phosphoric acid for 31P NMR. In some cases the total integral ratios in the 1H NMR were not precisely as expected; however, all other structural data are fully consistent with the proposed structures. Infrared absorption spectra were acquired using a PerkinElmer 1600 FTIR spectrometer. Phosphonium salts were examined by applying a concentrated deuterochloroform solution to NaCl discs followed by evaporation of the solvent in a nitrogen stream. Other samples were examined neat or as Nujol mulls between NaCl discs. Mass spectra were obtained from the Chemistry Department, University of Canterbury. Data are presented as m/z values for the parent molecular ion. Fluorescence measurements were made using a PerkinElmer MPF-3L fluorescence spectrophotometer.


    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

Redox Activity of Mitoquinone and Mitoquinol-- The mitochondrially targeted quinol, 10-(6'-ubiquinolyl)decyltriphenylphosphonium (4), and quinone, 10-(6'-ubiquinonyl)decyltriphenylphosphonium (5), were synthesized as shown in Scheme 1. Here they are called mitoquinol (reduced) and mitoquinone (oxidized), respectively, and mitoQ refers to a mixture of redox forms. As shown in Table I, mitoQ was intermediate in hydrophobicity between the simple phosphonium salt TPMP and the ubiquinone precursor bromodecyl ubiquinone (2). The distinctive absorption spectra of mitoquinone and mitoquinol are shown in Fig. 1A.


                              
View this table:
[in this window]
[in a new window]
 
Table I
The octanol/PBS partition coefficients were determined at 37 °C and are means ± S.E.M. of three separate determinations



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 1.   Absorption spectra of mitoquinol and mitoquinone. A, mitoQ (50 µM) was incubated with beef heart mitochondrial membranes (20 µg of protein/ml) for 1 h to oxidize it to mitoquinone. Reduction with NaBH4 (~250 µg) gave mitoquinol. B, 50 µM mitoQ was incubated with beef heart mitochondrial membranes, and the spectrum of mitoquinone was recorded (t = 0). Then antimycin (5 µM) and succinate (5 mM) were added, and further spectra were acquired at 5-min intervals (t = 5-25).

Electron Transfer between Mitochondria and mitoQ-- To determine whether the respiratory chain could reduce mitoquinone, we incubated it with beef heart mitochondrial membranes and recorded its spectrum (Fig. 1B, t = 0). Addition of the respiratory substrate succinate reduced mitoquinone to mitoquinol (Fig. 1B). Mitoquinone-mitoquinol interconversion was then measured continuously by monitoring mitoquinone at 275 nm (Fig. 2). Mitoquinone was reduced by beef heart mitochondrial membranes and succinate, and this reduction was blocked by the complex II inhibitor malonate (Fig. 2A). Chemically reduced mitoquinol was also oxidized by membranes, and this oxidation was blocked by the complex III inhibitor myxothiazol (Fig. 2B). Mitoquinol and mitochondrial membranes reduced ferricytochrome c and myxothiazol inhibited this reduction by 60-70% (data not shown). Rat liver mitochondria respiring on succinate or glutamate/malate reduced mitoquinone, and this activity was blocked by the respiratory inhibitors malonate (Fig. 2C) or rotenone (Fig. 2D), respectively. Dissipation of the membrane potential with the uncoupler FCCP also eliminated the reduction of mitoquinone by preventing its uptake into mitochondria (Fig. 2, C and D).



View larger version (17K):
[in this window]
[in a new window]
 
Fig. 2.   Reduction of mitoquinone and oxidation of mitoquinol by mitochondria. A, beef heart mitochondrial membranes (20 µg of protein/ml) were incubated with rotenone (8 µg/ml) and mitoQ (50 µM). A275 was monitored continuously and succinate (5 mM) and malonate (20 mM) were added where indicated. B, mitochondrial membranes were incubated as above with mitoquinol (50 µM), rotenone (8 µg/ml), and malonate (20 mM). Myxothiazol (10 µM) was added where indicated. When this experiment was repeated in the presence of ferricytochrome c (50 µM) and KCN (200 µM) the ferricytochrome c was reduced and this reduction was decreased by 60-70% by myxothiazol (data not shown). C and D, rat liver mitochondria (100 µg of protein/ml) were incubated in KCl, medium, and A275 was monitored. For the experiments shown in C, rotenone (8 µg/ml) and succinate (5 mM) were present and mitoQ (20 µM) was added where indicated. This experiment was repeated in the presence of malonate (20 mM) or FCCP (300 nM: not shown but identical to the experiment in the presence of malonate). For the experiments shown in D glutamate and malate (5 mM of each) were present and mitoQ (20 µM) was added where indicated. This experiment was repeated in the presence of rotenone (8 µg/ml) or FCCP (300 nM; not shown but identical to the experiment in the presence of rotenone).

Reduction of Mitoquinone by Respiratory Complexes-- To distinguish between mitoQ reactions with respiratory complexes and the endogenous ubiquinone/ubiquinol pool, we extracted beef heart mitochondrial membranes with pentane to remove endogenous ubiquinone. These mitochondria still oxidized mitoquinol and, in the presence of succinate, reduced mitoquinone by a malonate-sensitive pathway (Fig. 3A). This strategy was extended to investigate yeast that entirely lacked endogenous ubiquinone due to inactivation of ubiquinone biosynthesis. These yeast did not grow on the nonfermentable carbon source YPEG until the short-chain ubiquinone analog Q2 was added, but addition of mitoQ did not lead to cell growth (Fig. 3B). When respiratory chain activity was measured in mitochondria isolated from these yeast, there was no electron flux from NADH or succinate to cytochrome c until Q2 was added (Fig. 3, C and D). MitoQ did stimulate myxothiazol-sensitive cytochrome c reduction, but less so than Q2 (Fig. 3, C and D). When ubiquinone reduction was analyzed directly, mitochondria lacking ubiquinone reduced both Q2 and mitoquinone, however, the rate for mitoquinone was slower than for Q2 (Fig. 3E). The rate of reduction of mitoquinone by mitochondria was similar in the presence or absence of endogenous ubiquinone (Fig. 3, E and F). We conclude that mitoQ can be reduced and oxidized by the mitochondrial respiratory chain and that this is primarily through the active sites of respiratory complexes rather than via the endogenous ubiquinone pool (14, 28).



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 3.   Reduction of mitoquinone by ubiquinone-depleted mitochondria. A, pentane-extracted beef heart mitochondrial membranes (50 µg of protein/ml) were incubated with mitoQ (50 µM), and A275 was monitored continuously. Succinate (5 mM) and malonate (20 mM) were added where indicated. B, CY4.Delta Coq3 yeast were grown in YPEG medium with either no additions (open triangles) or supplemented with 50 µM Q2 (open squares) or 50 µM mitoQ (filled squares), and growth was analyzed by measuring A600 over time. Addition of mitoQ up to 250 µM or daily additions of 5 µM mitoQ did not lead to cell growth (data not shown). Results show a typical experiment that was repeated several times and similar results were obtained when the CenDelta Coq3 yeast strain was used. C-E, mitochondria from the CY4.Delta Coq3 yeast strain were freeze-thawed and suspended at 50 µg of protein/ml and ferricytochrome c reduction measured at 550 nm. C, 125 µM NADH, 50 µM ferricytochrome c, and 2 mM KCN were present with or without myxothiazol (myx; 10 µM). 10 µM Q2 or 25 µM mitoQ were added as indicated. D, 10 mM succinate was present; myxothiazol (myx; 10 µM), 10 µM Q2, or 25 µM mitoQ were added as indicated; and ferricytochrome c reduction was measured at 550 nm. E, 10 µM Q2 or 25 µM mitoQ were added to freeze-thawed mitochondria respiring on 10 mM succinate, and ubiquinone reduction was monitored continuously at 275 nm. The inhibition of mitoQ reduction by malonate (20 mM) is shown. F, the experiments shown in E were repeated using normal mitochondria isolated from the wild type CY4 strain.

Uptake of mitoQ by Isolated Mitochondria-- Tritiated mitoQ was taken up rapidly by energized mitochondria, and addition of the uncoupler FCCP caused its immediate efflux (Fig. 4A). This FCCP-sensitive accumulation of mitoQ was substantial up to 20 µM mitoQ (Fig. 4B). The mitoQ accumulation ratios were measured relative to the simple lipophilic cation TPMP over a range of membrane potentials (Fig. 4C). At low membrane potential, the mitoQ accumulation ratio was greater than for TPMP, but at high potentials the maximum accumulation ratio for mitoQ (~500-600) was slightly less than that for TPMP (~1300), suggesting that the greater hydrophobicity of mitoQ decreases its uptake slightly relative to TPMP.



View larger version (32K):
[in this window]
[in a new window]
 
Fig. 4.   Uptake of mitoQ by energized mitochondria. A, rat liver mitochondria were incubated in KCl medium supplemented with 10 mM succinate, rotenone (8 µg/ml), nigericin (1 µg/ml), 10 µM mitoQ, and 2.5 nCi of [3H]mitoQ/ml. Mitochondrial mitoQ uptake was determined at various times (filled squares). Where indicated, 300 nM FCCP was added after 2.5-min mitoQ accumulation (open circles). This gave the same final mitoQ accumulation as when FCCP was present from the start of the incubation (data not shown). Data are means of duplicate determinations. In all cases the range is smaller than the symbols. This shows a typical experiment, which was repeated on two separate mitochondrial preparations. B, the mitoQ accumulation ratio (µl/mg of protein) was determined by incubating mitochondria for 5 min with various concentrations of mitoQ in the absence (closed bars) or presence (open bars) of 300 nM FCCP. Data are means ± range of duplicate determinations and are typical of experiments repeated on two mitochondrial preparations. C, the mitoQ and TPMP accumulation ratios were determined in parallel by carrying out incubations in the presence of 5 µM mitoQ and 1 µM TPMP supplemented with either [3H]mitoQ or [3H] TPMP. A range of different membrane potentials was established by including FCCP (300 nM) or different concentrations of malonate (0-16 mM) in the incubations. mitoQ and TPMP accumulation ratios were determined in duplicate for each condition and are plotted against each other ± range. This figure combines data from two separate mitochondrial preparations. The membrane potential at the top of the panel was calculated from the TPMP accumulation ratio. D, mitochondria were incubated for 5 min in the presence of 300 nM FCCP and various concentrations of mitoQ (filled squares) or TPMP (open circles), and data are means of duplicate determinations. In the inset in D the amount of TPMP or mitoQ bound (nmol/mg of protein) is plotted against the concentration of TPMP or mitoQ added to the incubation (µM). In the main panel the reciprocal of the amount of TPMP or mitoQ bound is plotted against the reciprocal of the free concentration. For mitoQ the slope was 0.013, giving a bound-to-free ratio of 77 µl/mg of protein, whereas for TPMP the slope was 0.034, giving a bound-to-free ratio of 29 µl/mg of protein.

Location of mitoQ within Mitochondria-- Alkyltriphenylphosphonium cations equilibrate between the bulk phase and a potential energy well on the membrane surface where they adsorb as a monolayer close to the carbonyl groups of the phospholipid fatty acids (41-43). This adsorption is described by beta , the ratio of the surface density of adsorbed ions to their volume density in the bulk phase (42). We measured the nonspecific adsorption of mitoQ and TPMP to de-energized mitochondria over a range of concentrations and determined the ratio of adsorbed to free cations from double-reciprocal plots (Fig. 4D). From these and the surface area of rat liver mitochondria (155 and 520 cm2/mg of protein for the outer and inner membranes, respectively (44)) we calculated beta  = 22 × 10-6 cm for TPMP and beta  = 57 × 10-6 cm for mitoQ, values which are comparable to those of tetraphenylphosphonium adsorption to simple phospholipid bilayers (beta  = 4.2 × 10-6 cm (42)). An earlier study showed that the greater adsorption of decyltriphenyl phosphonium relative to TPMP was due to the increased entropy change for insertion of the alkyl group into the lipid bilayer, whereas the enthalpy change for cation adsorption was unaffected (42). This suggests that mitoQ adsorbs to membranes about three times more strongly than TPMP because of insertion of its hydrophobic side chain into the lipid bilayer (41). We conclude that mitoQ is taken up into energized mitochondria and is then largely adsorbed to the matrix face of the inner membrane with the phosphonium cation at the level of the fatty acid carbonyls while the hydrophobic side chain inserts into the lipid interior of the membrane.

Uptake of mitoQ by Mitochondria within Cells-- Tritiated mitoQ incubated with a suspension of 143B osteosarcoma cells was taken up over 20-40 min, and this uptake was decreased by disrupting the mitochondrial membrane potential (Fig. 5A). To determine the location of mitoQ within cells, we disrupted the plasma membrane of cells with the detergent digitonin and pelleted the mitochondria by centrifugation through oil (Fig. 5, B and C). This separated cells into mitochondrially enriched and cytosolic fractions, as confirmed by the distribution of the mitochondrial and cytosolic marker enzymes citrate synthase and lactate dehydrogenase (Fig. 5B). About half the mitoQ within the cell was found in mitochondrial fraction, similar to the proportion of mitoQ uptake sensitive to FCCP (Fig. 5C). Therefore, substantial amounts of mitoQ are taken up by both isolated mitochondria and mitochondria within cells, driven by the mitochondrial membrane potential.



View larger version (14K):
[in this window]
[in a new window]
 
Fig. 5.   Uptake of mitoQ by cells. A, 143B cells (5 × 106) were incubated in 500 µl of DMEM/HEPES supplemented with 5 µM [3H]mitoQ (filled squares). These incubations were repeated in the presence of 4 µM FCCP (open triangle) or with a mixture of FCCP, valinomycin, ouabain, and oligomycin (open circles). Data are means ± range of two determinations, and this is a typical experiment that was repeated on three separate cell incubations. B, cells were incubated as above for 60 min with 5 µM mitoQ, and then intact cells were pelleted through oil (no additions) or the cells were treated with digitonin and the mitochondria pelleted through oil (plus digitonin). Citrate synthase (open bars) and lactate dehydrogenase (closed bars) activities were then measured in the pellet and supernatant fractions, and the proportion of the total activity that was found in the pellet was calculated. Data are means ± S.D. of determinations on three separate cell preparations. C, cells were incubated as above with 5 µM [3H]mitoQ in the presence or absence of 4 µM FCCP, and then intact cells were pelleted through oil (cell) or the cell suspension was treated with digitonin and the mitochondria were pelleted through oil (mito). Data are means ± S.D. of experiments on four independent cell preparations.

Low Toxicity of mitoQ to Mitochondria and Cells-- The toxicity of mitoQ was investigated in mitochondria and cells. Up to 10 µM mitoQ had little effect on the membrane potential of isolated mitochondria but at 25 µM and above the potential decreased (Fig. 6A). For mitochondria respiring on either succinate or glutamate/malate, 10 µM mitoQ had little effect on uncoupled or phosphorylating respiration, but was inhibitory at 25-50 µM (Fig. 6, B and C). MitoQ stimulated coupled respiration by increasing the proton leak though the inner membrane; this effect was minimal for succinate at 10 µM but was noticeable at 10 µM for glutamate/malate (Fig. 6C). MitoQ toxicity to human 143B cells was determined from the release of lactate dehydrogenase into the culture medium over 24 h (Fig. 6D). MitoQ up to 10 µM did not affect cell viability, and concentrations of 25-50 µM were required for substantial cell death (Fig. 6D). In summary, mitoQ concentrations up to 10 µM do not disrupt mitochondrial or cell function and, therefore, concentrations of 1-5 µM were used in subsequent experiments.



View larger version (30K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of mitoQ on mitochondrial and cell function. A, the membrane potential of mitochondria respiring on succinate was measured in the presence of mitoQ. Data are expressed as a percentage of the membrane potential in the absence of mitoQ and are the means ± S.E. of measurements on three separate mitochondrial preparations. B and C, rates of coupled (closed bars), phosphorylating (open bars), and uncoupled (stippled bars) respiration were measured for mitochondria respiring on succinate (B) or glutamate and malate (C). Data are a percentage of the corresponding respiration rates in the absence of mitoQ and are the means ± S.E. of determinations on three separate mitochondrial preparations. In D mitoQ was incubated with 143B cells for 24 h, and LDH release into the culture medium was measured and expressed as a percentage of the total amount of LDH present in untreated wells. Data are means ± S.D. of three independent experiments.

Antioxidant Properties of mitoQ-- To investigate the antioxidant efficacy of mitoQ, we incubated mitochondria with cis-parinaric acid (Fig. 7A). This fatty acid fluoresces within a lipid environment, and its conjugated double bond fluorophore is susceptible to oxidation. Consequently, the disappearance of fluorescence is a measure of lipid peroxidation (34). In the presence of mitochondria, cis-parinaric acid fluoresced due to its insertion into lipid bilayers (Fig. 7A). MitoQ prevented the oxidation of cis-parinaric acid by hydrogen peroxide and ferrous iron, demonstrating that mitoquinol is an antioxidant (Fig. 7A). To quantitate the antioxidant efficacy of mitoQ, mitochondria were incubated with ferrous iron, and the accumulation of MDA was measured as a marker of lipid peroxidation (Fig. 7B). This oxidative damage also disrupted mitochondrial function as indicated by a decrease in the membrane potential (Fig. 7C). Incubation with mitoQ prevented both the accumulation of MDA and the disruption to mitochondrial function caused by oxidative stress (Fig. 7, B and C). To determine whether mitoquinone or mitoquinol was the effective antioxidant, we oxidized mitoQ to mitoquinone and prevented its reduction by the respiratory chain by including malonate and rotenone in the incubation. Under these conditions, mitoquinone did not block lipid peroxidation (Fig. 7D). In contrast, when mitoQ was reduced to mitoquinol by the respiratory chain, oxidative damage was prevented (Fig. 7D). The simple lipophilic cation TPMP did not prevent lipid peroxidation (Fig. 7D). Therefore, the antioxidant activity of mitoQ is due to its ubiquinol moiety.



View larger version (34K):
[in this window]
[in a new window]
 
Fig. 7.   Antioxidant efficacy of mitoQ. A, rat liver mitochondria were incubated with 10 mM succinate, 8 µg/ml rotenone, 50 µM ferrous sulfate, 100 µM ascorbic acid, and 1 mM hydrogen peroxide in the presence or absence of 5 µM mitoQ. Where indicated, 3 µM cis-parinaric acid was added and the fluorescence measured. Data are from a typical experiment repeated on three separate mitochondrial preparations. TPMP (5 µM) did not block cis-parinaric acid oxidation (data not shown). B, mitochondria were preincubated with 10 mM succinate and mitoQ for 5 min, and then a sample was taken for TBARS analysis (zero time). Ferrous sulfate (100 µM) and 300 µM ascorbic acid were then added, and 40 min later MDA formation was quantitated. Data are means ± range of duplicate determinations and are typical of experiments repeated on three separate mitochondrial preparations. C, mitochondria were incubated as described for B, isolated by centrifugation, and their membrane potential determined from the uptake of TPMP while respiring on glutamate/malate. Data are means ± range of a typical experiment repeated on three separate mitochondrial preparations. D, mitochondria were incubated as in B supplemented with 8 µg/ml rotenone. Succinate (5 mM) and mitoQ or TPMP (5 µM) were added to some incubations, whereas for the other incubations malonate (20 mM) was present and mitoQ was oxidized completely to mitoquinone before addition by incubation at basic pH. After preincubation for 5 min, ferrous sulfate (50 µM) was added, and 40 min later MDA formation was quantitated. Data are means ± range of duplicate determinations.

Recycling of mitoQ by the Respiratory Chain-- To determine whether mitoquinol was recycled by the respiratory chain after detoxifying a reactive oxygen species, we studied its interaction with peroxynitrite, a biologically significant oxidant formed from nitric oxide and superoxide (45-47). Because the half-life of peroxynitrite is only 1-2 s, mitoquinol regeneration from mitoquinone can be studied after all the added peroxynitrite has decomposed (45). Mitoquinol was rapidly oxidized to mitoquinone by peroxynitrite, however, mitoquinone was only detected when its reduction by the respiratory chain was prevented by malonate (Fig. 8A, upper trace). Continuous monitoring of the mitoquinone concentration showed that peroxynitrite rapidly oxidized the mitoquinol to mitoquinone, which was then reduced to mitoquinol by the respiratory chain (Fig. 8B). When malonate was present, this reduction by the respiratory chain was prevented (Fig. 8B). We conclude that mitoQ is an effective antioxidant that can be recycled to its active form by the respiratory chain after detoxifying a reactive oxygen species.



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 8.   Regeneration of mitoquinol after oxidation by peroxynitrite. A, beef heart mitochondrial membranes (100 µg of protein/ml) were incubated in 50 mM potassium phosphate, pH 7.4, at 20 °C with 50 µM mitoQ and 10 mM succinate. The lower trace (-peroxynitrite) shows that this treatment reduced all of the mitoQ to mitoquinol. Then malonate (20 mM) was added to prevent further reduction, and finally, peroxynitrite (200 µM) was added and the spectrum of mitoquinone was acquired (+peroxynitrite). When peroxynitrite was added without malonate the spectrum obtained was similar to that of mitoquinol (-peroxynitrite). B, beef heart mitochondrial membranes were incubated with 50 µM mitoQ and succinate (5 mM) as above, and the mitoquinone concentration monitored continuously at 275 nm. Where indicated peroxynitrite (500 µM) was added alone (-malonate), or in the presence of 20 mM malonate (+malonate; dashed line).

Prevention of Apoptosis by mitoQ-- A range of stimuli induce apoptosis by releasing cytochrome c from mitochondria into the cytoplasm, where it activates caspases. These include the oxidant hydrogen peroxide (8), the protein kinase C inhibitor staurosporine (40), and tumor necrosis factor-alpha (48). The mechanisms by which these stimuli cause cytochrome c release from mitochondria are unclear, but some or all may involve increased mitochondrial oxidative stress. Of particular interest is whether cytochrome c release induced by hydrogen peroxide is caused directly by mitochondrial oxidative damage or is a secondary consequence of cytoplasmic redox changes (8). A mitochondrially targeted antioxidant can help elucidate the role of mitochondrial oxidative damage in apoptosis, because it would only block those apoptotic signals that require mitochondrial oxidative stress. Therefore, we investigated the effect of mitoQ on apoptotic cell death.

Addition of hydrogen peroxide to Jurkat cells led to caspase activation and induction of apoptotic cell death 4-6 h later (Fig. 9). Preincubation with 1 µM mitoQ completely blocked caspase activation (Fig. 9, A and B) and substantially decreased apoptotic cell death, as determined by the proportion of annexin-positive cells (Fig. 9, C and D). To determine whether the mitochondrial localization of mitoQ was required for this protective effect, we compared mitoQ with Q1, a quinol antioxidant that distributes evenly throughout the cell, and found that Q1 did not block caspase activation (Fig. 9B). In contrast to the situation with hydrogen peroxide, mitoQ did not prevent apoptosis in Jurkat cells treated with staurosporine (40) or in WEHI 164 cells treated with tumor necrosis factor-alpha (49) (data not shown). We conclude that mitoQ blocks apoptosis induced by hydrogen peroxide. Because mitochondrial localization of the antioxidant is required to prevent apoptosis, mitochondrial oxidative stress may be a critical step in hydrogen peroxide-induced apoptosis but not for apoptosis following treatment with staurosporine or tumor necrosis factor-alpha .



View larger version (29K):
[in this window]
[in a new window]
 
Fig. 9.   Prevention of apoptosis by mitoQ. A, Jurkat cells (5 × 106) in 5 ml of medium were preincubated for 30 min with no additions (open circles) or with 1 µM mitoQ (filled circles), then 150 µM hydrogen peroxide was added and cells were harvested at various times and their caspase activity was measured as the rate of DEVD-AMC cleavage. Without hydrogen peroxide there was no caspase activation either in the absence (open squares) or presence of 1 µM mitoQ (filled squares). Preincubation with 1 µM TPMP did not decrease caspase activation by hydrogen peroxide (filled triangle). The figure shows a typical experiment repeated on five separate cell preparations. B, Jurkat cells incubated with 1 µM mitoQ or Q1 were treated with 150 µM hydrogen peroxide and 6 h later their caspase activity compared with cells treated with hydrogen peroxide alone. This figure shows typical experimental traces for caspase assays. C and D, Jurkat cells were treated with 150 µM hydrogen peroxide in the presence or absence of 1 µM mitoQ, cells were harvested at various times and annexin V binding analyzed by flow cytometry. C shows results from a typical experiment to measure the annexin V binding of cells harvested 6 h after treatment with 150 µM hydrogen peroxide in the presence or absence of 1 µM mitoQ. D shows measurements of the proportion of annexin V-positive cells at various times after addition of 150 µM hydrogen peroxide in the absence (open circles) or presence (filled circles) of 1 µM mitoQ. Cells incubated in the presence (filled squares) or absence (open squares) of 1 µM mitoQ without hydrogen peroxide treatment are also shown. Data are means ± range of duplicate determinations, and the experiment was repeated on two cell preparations with similar results.

Conclusion-- To provide new approaches to investigate the role of mitochondrial oxidative damage in cell death, we synthesized a mitochondrially targeted antioxidant, mitoQ, comprising a ubiquinone attached to a triphenylphosphonium lipophilic cation. The ubiquinone moiety was found to cycle between its oxidized (mitoquinone) and reduced (mitoquinol) forms by exchanging electrons with the respiratory chain. Mitoquinol was an effective antioxidant protecting mitochondria from oxidative damage and was rapidly regenerated by the respiratory chain after detoxifying a reactive oxygen species. As anticipated, the triphenylphosphonium cation led to the rapid and reversible accumulation of mitoQ by isolated mitochondria and by mitochondria within cells. Therefore, mitoQ is a mitochondrial-specific antioxidant.

We then used mitoQ to help elucidate the role of mitochondrial oxidative damage in apoptotic cell death. As a first step we showed that mitoQ prevented apoptosis caused by hydrogen peroxide but not that caused by staurosporine or tumor necrosis factor-alpha . This suggests that mitochondrial oxidative damage plays an important role in hydrogen peroxide-induced apoptosis but is not required for apoptosis induced by staurosporine or tumor necrosis factor-alpha . Further work using these and other mitochondrially targeted compounds to dissect out the role of mitochondrial oxidative changes in hydrogen peroxide-induced apoptosis is ongoing. The findings reported here demonstrate that mitochondrially targeted antioxidants such as mitoQ can be used to investigate the role of mitochondrial oxidative stress in cell death. This strategy also has potential for unraveling the contribution of oxidative stress to other pathologies involving mitochondrial dysfunction.


    ACKNOWLEDGEMENTS

We thank Prof. Cathy Clarke, UCLA and Prof. Ian Dawes, University of New South Wales, Sydney for supplying yeast strains.


    FOOTNOTES

* This work was supported in part by grants (to M. P. M. and R. A. J. S.) from the Health Research Council of New Zealand and from the Marsden Fund, administered by the Royal Society of New Zealand.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ A Foundation for Research, Science and Technology Bright Futures Scholar.

|| A New Zealand Science and Technology postdoctoral research fellow.

** A Health Research Council repatriation fellow.

Dagger Dagger To whom correspondence should be addressed: Medical Research Council-Dunn Human Nutrition Unit, Wellcome Trust/MRC Bldg, Hills Rd. Cambridge CB2 2XY, UK. Tel.: 44-1223-252703; Fax: 44-1223-252705; E-mail: michael.murphy@stonebow.otago.ac.nz.

Published, JBC Papers in Press, November 22, 2000, DOI 10.1074/jbc.M009093200


    ABBREVIATIONS

The abbreviations used are: IR, infrared; AMC, aminomethylcoumarin; DMEM, Dulbecco's modified Eagle's medium; FCCP, carbonyl cyanide p-trifluoromethoxyphenylhydrazone; LDH, lactate dehydrogenase; MDA, malondialdehyde; mitoquinol, 10-(6'-ubiquinolyl)decyltriphenylphosphonium; mitoquinone, 10-(6'-ubiquinonyl)decyltriphenylphosphonium; mitoQ, mixture of mitoquinol and mitoquinone; Q1, ubiquinone-1; Q2, ubiquinone-2; TBARS, thiobarbituric acid-reactive species; TPMP, methyltriphenylphosphonium cation; PBS, phosphate-buffered saline; MOPS, 4-morpholinepropanesulfonic acid.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES


1. Wallace, D. C. (1999) Science 283, 1482-1488[Abstract/Free Full Text]
2. Ames, B. N., Shigenaga, M. K., and Hagen, T. M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 7915-7922[Abstract/Free Full Text]
3. Ames, B. N., Shigenaga, M. K., and Hagen, T. M. (1995) Biochim. Biophys. Acta 1271, 165-170[Medline] [Order article via Infotrieve]
4. Beckman, K. B., and Ames, B. N. (1998) Physiol. Rev. 78, 547-581[Abstract/Free Full Text]
5. Michikawa, Y., Mazzucchelli, F., Bresolin, N., Scarlato, G., and Attardi, G. (1999) Science 286, 774-779[Abstract/Free Full Text]
6. Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., and Vogelstein, B. (1997) Nature 389, 300-305[CrossRef][Medline] [Order article via Infotrieve]
7. Kroemer, G., Dallaporta, B., and Resche-Rignon, M. (1998) Ann. Rev. Physiol. 60, 619-642[CrossRef][Medline] [Order article via Infotrieve]
8. Hampton, M. B., and Orenius, S. (1997) FEBS Lett. 414, 552-556[CrossRef][Medline] [Order article via Infotrieve]
9. Murphy, M. P. (1997) Trends Biotechnol. 15, 326-330[CrossRef][Medline] [Order article via Infotrieve]
10. Murphy, M. P., and Smith, R. A. J. (2000) Adv. Drug Delivery Rev. 41, 235-250[CrossRef][Medline] [Order article via Infotrieve]
11. Matthews, R. T., Yang, L., Browne, S., Bail, M., and Beal, M. F. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8892-8897[Abstract/Free Full Text]
12. Lass, A., Forster, M. J., and Sohal, R. S. (1999) Free Radic. Biol. Med. 26, 1357-1382[CrossRef][Medline] [Order article via Infotrieve]
13. Crane, F. L., and Barr, R. (1971) Methods Enzymol. 18C, 137-165
14. Crane, F. L. (1977) Annu. Rev. Biochem. 46, 439-469[CrossRef][Medline] [Order article via Infotrieve]
15. Lass, A., and Sohal, R. S. (1998) Arch. Biochem. Biophys. 352, 229-236[CrossRef][Medline] [Order article via Infotrieve]
16. Kagan, V. E., Serbinova, E. A., Stoyanovsky, D. A., Khwaja, S., and Packer, L. (1994) Methods Enzymol. 234, 343-354[Medline] [Order article via Infotrieve]
17. Maguire, J. J., Wilson, D. S., and Packer, L. (1989) J. Biol. Chem. 264, 21462-21465[Abstract/Free Full Text]
18. Ernster, L., Forsmark, P., and Nordenbrand, K. (1992) Biofactors 3, 241-248[Medline] [Order article via Infotrieve]
19. Takada, M., Ikenoya, S., Yuzuriha, T., and Katayama, K. (1984) Methods Enzymol. 105, 147-155[Medline] [Order article via Infotrieve]
20. Ingold, K. U., Bowry, V. W., Stocker, R., and Walling, C. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 45-49[Abstract]
21. Land, E. J., and Swallow, A. J. (1970) J. Biol. Chem. 245, 1890-1894[Abstract/Free Full Text]
22. Stoyanovsky, D. A., Osipov, A. N., Quinn, P. J., and Kagan, V. E. (1995) Arch. Biochem. Biophys 323, 343-351[CrossRef][Medline] [Order article via Infotrieve]
23. Mukai, K., Kikuchi, S., and Urano, S. (1990) Biochim. Biophys. Acta 1035, 77-82[Medline] [Order article via Infotrieve]
24. Liberman, E. A., Topali, V. P., Tsofina, L. M., Jasaitis, A. A., and Skulachev, V. P. (1969) Nature 222, 1076-1078[Medline] [Order article via Infotrieve]
25. Yu, C. A., and Yu, L. (1982) Biochemistry 21, 4096-4101[Medline] [Order article via Infotrieve]
26. Smith, R. A. J., Porteous, C. M., Coulter, C. V., and Murphy, M. P. (1999) Eur. J. Biochem. 263, 709-716[Abstract/Free Full Text]
27. Burns, R. J., Smith, R. A. J., and Murphy, M. P. (1995) Arch. Biochem. Biophys. 322, 60-68[CrossRef][Medline] [Order article via Infotrieve]
28. Cabrini, L., Landi, L., Pasquali, P., and Lenaz, G. (1981) Arch. Biochem. Biophys. 208, 11-19[Medline] [Order article via Infotrieve]
29. Chappell, J. B., and Hansford, R. G. (1972) in Subcellular Components: Preparation and Fractionation (Birnie, G. D., ed) , pp. 77-91, Butterworths, London
30. Smith, A. L. (1967) Methods Enzymol. 10, 81-86
31. Gornall, A. G., Bardawill, C. J., and David, M. M. (1949) J. Biol. Chem. 177, 751-766[Free Full Text]
32. Scott, I. D., and Nicholls, D. G. (1980) Biochem. J. 186, 21-33[Medline] [Order article via Infotrieve]
33. Brown, G. C., and Brand, M. D. (1985) Biochem. J. 225, 399-405[Medline] [Order article via Infotrieve]
34. Tribble, D. L., van den Berg, J. J. M., Motchnik, P. A., Ames, B. N., Lewis, D. M., Chait, A., and Krauss, R. M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 1183-1187[Abstract]
35. Packer, M. A., and Murphy, M. P. (1994) FEBS Lett. 345, 237-240[CrossRef][Medline] [Order article via Infotrieve]
36. Hughes, M. N., and Nicklin, H. G. (1968) J. Chem. Soc. A, 450-452
37. Grant, C. M., MacIver, F. H., and Dawes, I. W. (1997) FEBS Lett. 410, 219-222[CrossRef][Medline] [Order article via Infotrieve]
38. Glick, B. S., and Pon, L. (1995) Methods Enzymol. 260, 213-233[Medline] [Order article via Infotrieve]
39. Burns, R. J., and Murphy, M. P. (1997) Arch. Biochem. Biophys. 339, 33-39[CrossRef][Medline] [Order article via Infotrieve]
40. Scarlett, J. L., Sheard, P. W., Hughes, G., Ledgerwood, E. C., Ku, H.-H., and Murphy, M. P. (2000) FEBS Lett. 475, 267-272[CrossRef][Medline] [Order article via Infotrieve]
41. Ono, A., Miyauchi, S., Demura, M., Asakura, T., and Kamo, N. (1994) Biochemistry 33, 4312-4318[Medline] [Order article via Infotrieve]
42. Flewelling, R. F., and Hubbell, W. L. (1986) Biophys. J. 49, 531-540[Abstract]
43. Flewelling, R. F., and Hubbell, W. L. (1986) Biophys. J. 49, 541-552[Abstract]
44. Schwerzmann, K., Cruz-Orive, L. M., Eggman, R., Sanger, A., and Weibel, E. R. (1986) J. Cell Biol. 102, 97-103[Abstract]
45. Beckman, J. S., Beckman, T. W., Chen, J., Marshall, P. A., and Freeman, B. A. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 1620-1624[Abstract]
46. Murphy, M. P., Packer, M. A., Scarlett, J. L., and Martin, S. W. (1998) Gen. Pharmacol. 31, 179-186[CrossRef][Medline] [Order article via Infotrieve]
47. Schopfer, F., Riobo, N., Carreras, M. C., Alvarez, B., Radi, R., Boveris, A., Cadenas, E., and Poderoso, J. J. (2000) Biochem. J. 349, 35-42[CrossRef][Medline] [Order article via Infotrieve]
48. Luo, X., Budihardjo, I., Zou, H., Slaughter, C., and Wang, X. (1998) Cell 94, 481-490[Medline] [Order article via Infotrieve]
49. Faraco, P. R., Ledgerwood, E. C., Vandenabeele, P., Prins, J. B., and Bradley, J. R. (1999) Biochem. Biophys. Res. Commun. 261, 385-392[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.